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Novel implementation research designs 
for scaling up global mental health care: 
overcoming translational challenges to address 
the world’s leading cause of disability
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Abstract 
Despite established knowledge that Low and Middle Income Countries (LMICs) bear the majority of the world’s bur-
den of mental disorders, and more than a decade of efficacy research showing that the most common disorders, such 
as depression and anxiety, can be treated using readily available local personnel in LMICs to apply evidence-based 
treatments, there remains a massive mental health treatment gap, such that 75 % of those in LMICs never receive care. 
Here, we discuss the use of a new type of implementation science study design, the effectiveness-implementation 
hybrids, to speed the translation and scale up of mental health care in LMICs. We use our current study of Interper-
sonal Psychotherapy (IPT) delivered by local personnel for depression and trauma-related disorders among HIV+ 
women in Kenya as an example of effectiveness-implementation hybrid design for mental health services research in 
LMICs.
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Twenty years of rising mental disorder burden 
in LMICs
The 1996 global burden of disease (GBD) report by WHO 
and the World Bank was the first to put mental disorders 
on the list of highly disabling conditions. Twenty years 
later, the global disability attributed to mental disorders 
has increased by 45 % rendering them the leading cause 
of years lived with disability. While many low resource 
populations with unmet mental health care needs exist 
within high income countries (HICs), according to the 
GBD studies, the majority of the burden is carried by low 
and middle income countries (LMICs), where 75  % of 
those in need of mental health treatment never receive 
any care. The 2011 world economic forum projected that 
mental disorders would account for over half of the total 
economic burden from non-communicable diseases over 
the next two decades. The most common mental disor-
ders in LMICs are depression and anxiety [including 
posttraumatic stress disorder (PTSD)] among adults [1], 
illnesses for which treatments with strong efficacy have 
been widely used in HICs for decades.
Advances in treatment
Non‑specialists can treat common mental disorders in low 
resource settings
While the scarcity of mental health care providers was 
initially recognized as a contributor to high burden in 
LMICs, we now have a decade of studies showing that 
evidence-based treatments for depression and anxiety 
disorders, such as brief, structured psychotherapies, are 
feasible, acceptable and have strong effectiveness when 
delivered by local non-specialist personnel in LMICs [2]. 
However, with a few exceptions, most treatment studies 
in LMICs use traditional effectiveness designs, often fore-
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science methodology—the goal of which is to identify 
practice and policy tools and strategies for successfully 
scaling up evidence-based interventions.
Cost of inaction: the economics of mental health
Unlike diseases for which treatment costs contribute the 
majority of their economic burden, the costs associated 
with mental disorders are the costs of inaction. Depres-
sion, which is the most common mental disorder among 
adults, is notorious for its economic impact. Relative to 
other common diseases in working-age adults, depres-
sion has an earlier age of onset (often twenties) and 
higher chronicity. Depression impacts economic output 
through its association with work absenteeism (miss-
ing work) and decreased productivity (30 % decline with 
mild depression). However, in HICs, depression and its 
associated economic losses are more than reversible with 
improved access to treatment. Studies have shown that 
investments in depression treatment have net return rates 
of over 300 % [3].
An urgent need to scale
As global citizens, we have known for two decades that 
treatable mental disorders inflict disability on a mas-
sive number of people, the majority of whom reside in 
LMICs. We have known for one decade that evidence-
based, effective, low cost treatments can be delivered by 
non-specialist personnel in low resource settings. We 
have strong data to suggest net positive returns on men-
tal health care for depression, the most common mental 
disorder. Yet, we have not succeeded in improving wide-
spread access to evidence-based treatment for common 
mental disorders in LMICs.
Applying new implementation designs to global mental 
health: stimulating progress
Implementation science addresses the “know-do” gap in 
healthcare: the disparity between what scientific research 
identifies as the best evidence-based practices, and what 
is actually done in the community. Studies suggest that it 
takes an average of 17 years for 14 % of original research 
to be integrated into physician practice and that only 
54  % of US adults receive care that meets indicators of 
high quality [4].
Implementation science improves the efficiency and 
impact of health care by informing the integration of 
evidence-based practices into clinical and community 
setting. Specifically, implementation researchers seek to 
disrupt use of the traditional “pipeline” model in which 
research progresses sequentially from basic science to 
treatment development and efficacy aiming to establish 
internal validity, followed occasionally by effectiveness 
and implementation studies to evaluate external valid-
ity. Implementation science focuses on the processes like 
financing, provider training and supervision, workflow and 
evidence-based practice demand through which effica-
cious interventions can be delivered within real-world set-
tings. Implementation science questions can be integrated 
within efficacy and effectiveness trials to speed progres-
sion from treatment development to wide-spread use.
Effectiveness‑implementation hybrid research designs
Blending efficacy, effectiveness and implementation 
stages of research is a recent strategy to speed knowl-
edge translation and produce evidence with greater 
relevance to practice and policy. Recently, Curran and 
colleagues defined effectiveness-implementation hybrid 
study designs [5]. Type I is recommended for situations 
in which the primary aim is to determine the effective-
ness of an intervention when used with broad eligibility 
criteria, approximating “real world” use, with a second-
ary aim to better understand the context for implemen-
tation. Type II places equal weight on effectiveness and 
implementation aims, while Type III prioritizes investi-
gation of the utility of an implementation intervention/
strategy with secondary aims to evaluate the clinical out-
comes associated with the implementation trial. Here, we 
provide an example of how effectiveness-implementation 
designs can be used to advance scale up of mental health 
care for common disorders in LMICs (Box 1).
Box 1 The category fallacy
Medical anthropology has a major influence on the field of global mental health (GMH), with psychiatrist and medical anthropologist, Dr. Arthur Klein-
man, conducting the first influential studies [6]. In some cases, anthropological research suggested that mental health diagnoses considered valid 
in one culture were not valid in populations that experienced and expressed emotions differently—the basis of the “category fallacy,” which led to 
debate about best practices in humanitarian aid and GMH treatment research. Partially reflecting the influence of medical anthropology, many treat-
ment research studies are tightly indexed to the target population, often preceded by an ethnographically informed needs assessment—emphasiz-
ing assessment of the internal validity of diagnosis and treatment for the local/target community. While medical anthropology and ethnographic 
tools must remain cornerstones of an ethical approach to GMH treatment research, we suggest that implementation science, particularly effectiveness-
implementation study designs, can build on this rich history, retaining a focus on internal validity while addressing today’s desperate need for broad 
scale up of mental health care for common disorders among diverse populations of adults in LMICs
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An effectiveness‑implementation hybrid type I case 
example: HIV‑positive women in Kenya
Setting
HIV infection in women is significantly associated with 
gender based violence (GBV) worldwide [7]. Survivors of 
GBV are at high risk of mental disorders, with 60–90 % 
developing posttraumatic stress disorder (PTSD) and/
or depression [8]. In the setting of HIV, depression and 
PTSD not only cause suffering and disability, but corre-
late with deficits in adherence to antiretroviral therapy 
(ART). Our study site is the family aids care education 
and services (FACES) HIV care and clinical research 
clinic in the Nyanza region of Kenya, which has the high-
est national prevalence of HIV (19.3 %) and physical vio-
lence against women (57 % of women aged 15–49).
Needs assessment
In 2013, we completed a needs assessment study of HIV+ 
women affected by GBV (HIV+GBV+) women served by 
FACES. As reported elsewhere [9], more than half of par-
ticipants described symptoms of depression, anxiety and 
traumatic stress among HIV+GBV+ women served by 
FACES. Participants identified problems with loss, tran-
sition and interpersonal conflict (Table  1). The coping 
skill identified by 82  % of study participants was social 
support from other HIV+ women. Women preferred to 
receive mental health treatment at the FACES clinic (ver-
sus separate location) and individual counseling was pre-
ferred over group treatment or medication.
Treatment selection: interpersonal psychotherapy (IPT)
Given that many sources of emotional distress were 
related to interpersonal loss, transition or conflict, we 
hypothesized that IPT will be an effective treatment 
for depression and PTSD among HIV+GBV+  women 
served by the FACES clinic because it will improve com-
munication and decision making around the identified 
problem area. Current coping skills, such as social sup-
port from other HIV+ women, suggest that IPT will be 
an acceptable treatment for this population, given that 
IPT mobilizes social support as a key strategy to enable 
effective management of the problem area. Our team and 
others have shown that IPT is feasible, acceptable and 
has strong efficacy in low resource settings, including 
delivery by non-specialists in sub-Saharan Africa.
Adaptation, training and manual
Evidence-based treatments are not always designed to 
be implemented in settings where they are most needed, 
requiring adaptation for the target population. Given 
the influence of culture on emotions, adaptation is often 
a key aspect of global mental health (GMH) treatment 
research (Box 2). In our adaptation of IPT, we focused on 
content and process, using data from our needs assess-
ment study with further adaptations during on-site train-
ing of prospective IPT therapists (local non-specialists) 
and pilot IPT cases (Table 1).
Study design
We are now using an effectiveness-implementation 
hybrid type I study design to deliver IPT integrated 
within the HIV care platform, in order to move efficiently 
toward implementation and scale up of mental health 
care, while monitoring individual clinical outcomes [5]. 
The hybrid type I design prioritizes evaluation of the 
effectiveness of the intervention (Table  2) with partici-
pant level randomization, but allows for data collection 
on implementation parameters (Table 3).
Table 1 Optimizing IPT for HIV+GBV+ women in Kenya with MDD and PTSD
a Chama informal cooperative group that pools and loans funds to group members; GBV gender based violence; HIV+ HIV-positive; HIV+GBV+ HIV-positive women 
affected by gender based violence; IPT interpersonal psychotherapy; PTSD posttraumatic stress disorder
IPT stage Adaptation
Summary of adaptations for meeting, inventory and formulation and termination phases
 Initial meetings (session 1–3) Medical model of depression and PTSD in the setting of HIV, method and goals of IPT, interpersonal inventory 
including key components for study population: Disclosure of HIV status and its effects on relationships, GBV, 
housing and social support
 Interpersonal formulation  
(sessions 4–5)
Local examples—
  Role conflict GBV, reproduction, condom use, HIV discordance in couple, inheritance
  Role transition HIV diagnosis, polygamy, single parenting, re-marriage, land disinheritance, separation from children
  Loss Family deaths secondary to HIV
 Middle sessions (6–10) Use local resources to advance social support around the identified problem area, including HIV women’s 
groups, women’s church groups and women’s chamasa
 Concluding (sessions 11–12) Review successes, relapse prevention strategies
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Summary and next steps
Despite evidence that common and treatable mental 
disorders are the leading global cause of disability and 
repeated calls for broad-scale implementation of mental 
health services in LMICs, GMH implementation research 
remains nascent. New effectiveness-implementation 
study designs allow for monitoring of clinical outcomes, 
while advancing research to support mental health care 
scale up. GMH now has: [1] twenty years of data on the 
burden (including the economic burden) of mental disor-
ders in LMICs; [2] a rapidly growing body of acceptable, 
feasible, culturally relevant and effective treatments for 
Table 2 A type I effectiveness-implementation hybrid trial design for global mental health: effectiveness
ART anti-retroviral therapy; FACES family AIDS, care, GBV education and services; gender based violence; HIV+ HIV-positive; IPT interpersonal psychotherapy; KEMRI 
Kenya medical research institute; MDD major depressive disorder; PEPFAR president’s emergency plan for AIDS relief; PTSD posttraumatic stress disorder; TAU 
treatment as usual; UCSF University of California, San Francisco
Study component Description
Treatment effectiveness: randomized controlled trial (RCT) within a routine clinical setting with minimal restrictions
 Target population HIV+ women affected by GBV with MDD and PTSD, enrolled in HIV care at the UCSF-KEMRI FACES clinic sup-
ported by PEPFAR, which treats >140,000 HIV+ individuals in the Nyanza region of Kenya
 Recruitment Study information provided in waiting area for self-referral, HIV clinic providers alerted to the study and eligibil-
ity criteria
 Eligibility HIV-infected women over age 18, enrolled in HIV care at FACES, PTSD secondary to GBV and MDD, absence 
of cognitive dysfunction, severe mood/thought disorders and substance abuse requiring a higher level/
alternate care (qualitative needs assessment suggested that these criteria would identify a high proportion of 
HIV+GBV+ women in need of mental health care at FACES)
 Intervention Participants will be randomized to receive: [1] 12 sessions of weekly IPT delivered at the FACES clinic plus FACES 
psychosocial treatment as usual (TAU) or [2] FACES TAU; TAU group is offered IPT at week 12
 Concurrent treatment Any mental health counseling/psychotherapy, psychotropic medication, ARV adherence counseling, couples 
therapy, other study participation and/or other psychosocial intervention at the FACES clinic or outside is 
allowed and noted
 Retention For missed sessions or evaluations, participants are called up to four times and emergency contact is alerted
 RCT outcomes Primary: diagnosis of MDD/PTSD; Secondary: continuous measures of depression and PTSD symptoms, inter-
personal functioning, anger, self-efficacy, substance use, quality of life, disability, HIV viral load, self-reported 
ARV adherence and neurocognitive functioning. Primary and secondary outcomes assessed at baseline and 
repeated at weeks 12, 24, 36
 IPT adaptation and therapist training Adaptations to IPT content and process to optimize fit while maintaining fidelity to IPT protocol, drawing on 
prior experience with IPT adaptation. Additional IPT adaptations were made based on feedback from therapist 
non-specialist trainees during 2 week formal IPT training and 12 week pilot cases
 Adherence to protocol Evaluated after each session by an IPT study supervisor, using a session-specific IPT adherence monitoring, 
consisting of 9–10 items scored on a 10 point likert scale, including a reverse coded item. All sessions are 
audio-recorded and a random 20 % of sessions are evaluated by an independent rater
 Sample size 220
 Data analysis Main analysis is comparison of change from baseline to post-treatment (12 weeks) between IPT+TAU and TAU. 
Maintenance of gains assessed by testing for significant change from 12 week to 24 and 36 week follow up 
assessments. Sub-group (sensitivity) analyses will be used to identify sub-groups for whom IPT+TAU is more 
or less effective
Box 2 Global mental health (GMH) implementation science: next steps
Study designs. Encourage explicit use of implementation science in GMH treatment studies, leveraging new hybrid 
effectiveness-implementation designs at early stages of investigation
    Integrate within priority care systems
    Engage a reciprocal partnership with local and national policy makers and opinion leaders as well as health and 
mental health practitioners and researchers in the early stages of the treatment study, focused on scaling up 
mental health care to address local needs
    Continue and extend the GMH history of context-dependent adaptations of interventions to improve fit with 
population needs and service setting
    Develop criteria for selection of study personnel for sustained, collaborative implementation
    Use explicit strategies to develop local, sustainable methods of supervising non-specialist providers
Study outcomes. Emphasize policy-relevant outcomes for GMH:
    Evaluate treatment effect on health co-morbidities (e.g., HIV viral load, neurocognitive deficits and other commu-
nicable and non-communicable diseases)
    Conduct cost analyses (e.g., cost-benefit and changes in economic productivity)
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depression and anxiety delivered by local non-specialist 
personnel; [3] access to emerging effectiveness-imple-
mentation study designs that can be incorporated into 
early stage treatment research to guide eventual scal-
ing-up. Now, more than ever, global health funders and 
global mental health researchers have the incentives and 
tools to partner with government, academic and opinion 
leaders and use implementation science to scale up men-
tal health care services for common mental disorders in 
LMICs.
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